Evoke Pharma Inc. Files DEF 14A on Executive Compensation

Evoke Pharma Inc DEF 14A Filing Summary
FieldDetail
CompanyEvoke Pharma Inc
Form TypeDEF 14A
Filed DateApr 10, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: executive-compensation, DEF-14A, equity-awards

TL;DR

Evoke Pharma DEF 14A out: Executive pay details for 2024, including equity awards for Gonyer and D'Onofrio.

AI Summary

Evoke Pharma Inc. filed a DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as Gonyer Member and D'Onofrio Member, with details on their fair value and vesting schedules.

Why It Matters

This filing provides transparency into how Evoke Pharma Inc. compensates its top executives, which can influence investor decisions and employee morale.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of executive compensation and does not inherently present new financial risks.

Key Players & Entities

  • Evoke Pharma Inc. (company) — Filer of the DEF 14A
  • Gonyer Member (person) — Executive receiving equity awards
  • D'Onofrio Member (person) — Executive receiving equity awards

FAQ

What is the primary purpose of this DEF 14A filing?

The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of Evoke Pharma Inc.'s executive officers and directors for the fiscal year ending December 31, 2024.

When was this DEF 14A filing submitted to the SEC?

This DEF 14A filing was submitted to the SEC on April 10, 2025.

What fiscal year does the compensation information in this filing primarily cover?

The compensation information in this filing primarily covers the fiscal year ending December 31, 2024.

Are there specific individuals mentioned in relation to equity awards?

Yes, the filing references equity awards for 'Gonyer Member' and 'D'Onofrio Member'.

What is Evoke Pharma Inc.'s Standard Industrial Classification (SIC) code?

Evoke Pharma Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 10, 2025 by Gonyer Member regarding Evoke Pharma Inc.

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.